Circ J 2009; 73: 750 -754 he lower incidence of atherosclerosis in premenopausal women than in men is an established epidemiological observation. 1 Menopause is also a well-known coronary risk factor, 2,3 but estrogen replacement therapy for postmenopausal women has not shown the hoped-for results in either primary (WHI: Women's Health Initiative) or secondary (HERS: Heart and Estrogen/Progestin Replacement Study) cardiovascular event prevention. [4][5][6] Even though large clinical studies such as HERS and WHI showed no additional benefit from exogenous estrogen to prevent atherosclerosis, we believe endogenous estrogen may help to prevent atherosclerosis. During normal menstrual cycles, women show high levels of estrogen just before ovulation and during the luteal phase. Previously we and other researchers reported that endothelium-dependent vasodilatation is increased in young women during the phases of their menstrual cycles when endogenous estrogen levels are high, 7 and pregnant women show significantly high levels of estrogen. Therefore, we hypothesized that if women have been exposed for a longer time and/or at a higher level to endogenous estrogen, they may obtain estrogen's beneficial "cardioprotective" or "anti-atherosclerosis" effect. To examine this hypothesis, we enrolled a substantial number of women and used a fairly simple measurement to evaluate clinical arteriosclerosis. Increased arterial stiffness, as reflected by an increased pulse wave velocity (PWV), is a risk factor for atherosclerotic cardiovascular disease. 3 PWV is a non-invasive technique widely used in the clinical setting, so we measured the brachial-ankle PWV (baPWV) as an indicator of arteriosclerosis. Although the baPWV reflects central and peripheral arterial stiffness, it is closely correlated with aortic arterial stiffness and the severity of atherosclerosis, 8 so we considered it might be useful as both a marker of cardiovascular risk and an indicator of clinical arteriosclerosis.In this cross-sectional study, we examined the association between pregnancy followed by delivery (number of both gravida and para) and the baPWV.
MethodsA total of 2,560 women undergoing an annual health screening examination at the institute of Hyogo Prefecture Health Promotion Association were recruited for the study (age range 22-83 years). Subjects with an ankle-brachial pressure index of less than 0.9 and with a significant arrhythmia such as atrial fibrillation, which may affect the results of PWV, were excluded from the study. Informed consent was obtained from all of the women who were enrolled and the study protocol was approved by the Ethics Committee of Hyogo Prefecture Health Promotion Association. The age at menarche, pregnancy history (number of both gravida and para), menopausal status and the use of estrogen replacement therapy were obtained by a selfreporting questionnaire, which was confirmed by medical staff at the Institute. Conventional coronary risk factors, (Received May 7, 2008; revised manuscript received November 7, 2...